Management Team

Tomasz Sablinski, M.D., Ph.D. - CEO

Dr. Sablinski is currently Head of Development and a Managing Director of Celtic Therapeutics Development. He founded TLS in 2010 stimulated by the opportunities to introduce a new model of drug development afforded by modern computer sciences, technology, and new communication and knowledge generation patterns. He has over thirty years of experience in healthcare. This includes fifteen years of pharmaceutical development in a major pharmaceutical company, a CRO, and consulting for small biotechnology companies. His experience in these roles include time in the United States, Europe and Japan. In the 1990s he was a member of Harvard Medical School (Brigham and Women's and Massachusetts General hospitals) teams conducting pioneering work in developing biologic immunosuppressive regimens, induction of transplantation tolerance and xenotransplantation. In parallel, and prior to this, he practiced as a surgeon specializing in renal transplantation and general surgery in his native Poland and in Boston. Transparency Life Sciences’ origins lie in a strong belief that the current system of drug development must be completely changed, and in a passion for development of medications at a fraction of current cost. He received his M.D. and Ph.D. from the Academy of Medicine in Warsaw.

Marc Foster - COO

Marc brings twelve years of biotech and fifteen years of high tech experience to TLS. Most recently, he served as a senior business development and technology advisor to FoldRx Pharmaceuticals, where he helped craft and implement the business development strategy of the company's protein misfolding pipeline and  discovery platform, leading to an acquisition by Pfizer in 2010. Marc began his biotech career working on behalf of Schrodinger in product development. Subsequently he co-founded and built Reify Corporation, developer of high-content assay systems for pre-clinical discovery and toxicology. During his high tech career Marc held operating, co-founding, and advisory roles with numerous firms that created substantial shareholder value through acquisition or public offering, including NETBot, Apropos, and InTouch Systems. Marc holds a BS in Electrical Engineering and a BA in English from Brown University, and a MBA in Finance from The University of Chicago Booth School of Business. He served as a Research Fellow at BIDMC/Harvard Medical School in Endocrinology.

Lawrence Steinman, M.D. - Chairman, Scientific Advisory Board

Dr. Steinman is a professor of neurology and neurological sciences, pediatrics, and genetics at Stanford School of Medicine. He is also the chair of the Stanford University Program in Immunology. Dr. Steinman’s research focuses on what provokes relapses and remissions in multiple sclerosis (MS), the nature of the genes that serve as a brake on brain inflammation, and the quest for a vaccine against MS. He has developed two antigen specific therapies, using DNA vaccines, for MS and type 1 diabetes. He was senior author on the seminal 1992 Nature article that reported the key role of a particular integrin in brain inflammation. This research led to the development of the drug Tysabri, which is used to treat patients with MS and Crohn’s disease. Dr. Steinman holds a number of patents in the areas of immunology, and for therapies of Huntington Disease and MS. He cofounded Neurocrine Biosciences, Bayhill Therapeutics, and Nuon Therapeutics. Dr. Steinman received his BA from Dartmouth College and his M.D. from Harvard University.